Related Experiment Video
Updated: Feb 9, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
Synthesis, molecular modelling studies and biological evaluation of new oxoeicosanoid receptor 1 agonists
Tomasz Maciej Stepniewski1, Mariona Torrens-Fontanals1, Ismael Rodríguez-Espigares1
1GPCR Drug Discovery Lab, Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM) - Department of Experimental and Health Sciences of Pompeu Fabra University (UPF), Barcelona, Spain.
Abstract:
The oxoeicosanoid receptor 1 (OXER1) is a member of the G-protein coupled receptors (GPCR) family, and is involved in inflammatory processes and oncogenesis. As such it is an attractive target for pharmacological intervention. The present study aimed to shed light on the molecular fundaments of OXER1 modulation using chemical probes structurally related to the natural agonist 5-oxo-ETE. In a first step, 5-oxo-ETE and its closely related derivatives (5-oxo-EPE and 4-oxo-DHA) were obtained by conducting concise and high-yielding syntheses. The biological activity of obtained compounds was assessed in terms of potency (EC50) and efficacy (Emax) for arrestin recruitment. Finally, molecular modelling and simulation were used to explore binding characteristics of 5-oxo-ETE and derivatives with the aim to rationalize biological activity. Our data suggest that the tested 5-oxo-ETE derivatives (i) insert quickly into the membrane, (ii) access the receptor via transmembrane helices (TMs) 5 and 6 from the membrane side and (iii) drive potency and efficacy by differential interaction with TM5 and 7. Most importantly, we found that the methyl ester of 5-oxo-ETE (1a) showed even a higher maximum response than the natural agonist (1). In contrast, shifting the 5-oxo group into position 4 results in inactive compounds (4-oxo DHA compounds (3) and (3a)). All in all, our study provides relevant structural data that help understanding better OXER1 functionality and its modulation. The structural information presented herein will be useful for designing new lead compounds with desired signalling profiles.
Insights
Researchers synthesized novel oxoeicosanoid receptor 1 (OXER1) modulators, revealing key interactions for drug design. A 5-oxo-ETE derivative demonstrated superior efficacy, offering new therapeutic avenues for inflammation and cancer.
Area of Science:
- Medicinal Chemistry
- Molecular Pharmacology
- Structural Biology
Background:
- Oxoeicosanoid receptor 1 (OXER1), a G-protein coupled receptor (GPCR), plays a role in inflammation and oncogenesis.
- OXER1 is a potential target for pharmacological interventions.
- Understanding OXER1 modulation is crucial for developing new therapeutics.
Purpose of the Study:
- To elucidate the molecular basis of OXER1 modulation.
- To synthesize and evaluate chemical probes structurally related to the natural agonist 5-oxo-ETE.
- To rationalize the biological activity of OXER1 modulators using molecular modeling.
Main Methods:
- Concise and high-yielding synthesis of 5-oxo-ETE and its derivatives (5-oxo-EPE, 4-oxo-DHA).
- Assessment of biological activity, including potency (EC50) and efficacy (Emax) for arrestin recruitment.
- Molecular modeling and simulation to explore ligand-receptor binding characteristics.
Main Results:
- Synthesized 5-oxo-ETE derivatives efficiently.
- Identified a methyl ester of 5-oxo-ETE (1a) with higher efficacy than the natural agonist.
- Determined that derivatives with the oxo group shifted to position 4 are inactive.
- Molecular modeling revealed that ligands access OXER1 from the membrane via TM5 and TM6, with differential interactions at TM5 and TM7 driving activity.
Conclusions:
- The study provides critical structural insights into OXER1 functionality and modulation.
- The findings are valuable for designing novel OXER1-targeting compounds with specific signaling profiles.
- This research advances the development of potential therapeutics for inflammatory diseases and cancer.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Molecular Models
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Preparation of 1° Amines: Azide Synthesis
Azide ions act as good nucleophiles and react with unhindered alkyl halides to form alkyl azides. Alkyl azides do not participate in further nucleophilic substitution reactions, thereby eliminating the chances of polyalkylated products. Alkyl azides are reduced by hydride-based reducing agents, like lithium aluminum...
Preparation of 1° Amines: Gabriel Synthesis
Strong bases like NaOH or KOH deprotonate the phthalimide to form the corresponding anion, which acts as a nucleophile. Further, the anion attacks an...

